Mirati Therapeutics Inc.
Clinical trials sponsored by Mirati Therapeutics Inc., explained in plain language.
-
New hope for Tough-to-Treat lung cancer: testing different doses of promising drug
Disease control Recruiting nowThis study is testing two different dosing schedules of the drug adagrasib to see which one works better for people with advanced lung cancer that has a specific genetic change called KRAS G12C. It is for patients whose cancer has continued to grow after trying standard chemother…
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for Tough-to-Treat lung cancer: major trial tests targeted drug combo
Disease control Recruiting nowThis study is testing whether adding a new targeted drug, adagrasib, to standard immunotherapy and chemotherapy works better for people with a specific type of advanced lung cancer. It will involve about 630 adults who have not yet received treatment for their advanced cancer and…
Phase: PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New Two-Drug attack on Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing whether a new drug called adagrasib works better alone or combined with an existing immunotherapy (pembrolizumab) for advanced lung cancer that has a specific genetic mutation called KRAS G12C. It will involve about 806 people who have not yet received treat…
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC